GERN Latest Report

Performance of the Quarterly Report

The operating revenue of Jielong (GERN) reached RMB47,537,000 as of December 31, 2024, a significant increase from RMB23,000 as of December 31, 2023. This change reflects the expansion of the company's business and the increase in market demand, showing its strong growth momentum.

Key Data in the Financial Report

1. Jielong's operating revenue jumped from RMB23,000 to RMB47,537,000, indicating a significant improvement in sales and services. This may be related to the launch of new products or the growth of market share.

2. The company's investment in research and development (R&D) (RMB23,433,000) began to bear fruit, with the launch of new products or technologies bringing in new sources of revenue.

3. Jielong may have effectively adjusted its marketing and sales strategies, improving its ability to acquire and retain customers.

4. As the industry demand grows, Jielong's revenue growth may be closely related to the improvement of the overall market environment.

Peer Comparison

1. Industry-wide analysis: In the biopharmaceutical industry, overall operating revenue may have experienced a recovery or growth, especially in high-growth areas. Although other companies in the industry may also benefit from changes in market demand, Jielong's revenue growth is significant, indicating its enhanced market competitiveness.

2. Peer evaluation analysis: According to data from the first three quarters of 2024, Jielong's operating revenue was US$29.457 million, a massive 13664.95% year-on-year growth. Compared to its peers, Jielong's performance in the market is particularly outstanding, demonstrating its leadership in the development of cancer treatment drugs.

Summary

Jielong's (GERN) operating revenue has grown significantly due to the launch of new products, increased market demand, and effective marketing strategies. Despite the overall sluggish industry growth, Jielong has demonstrated strong market competitiveness through its innovative drug development and positive performance in the capital market.

Opportunities

1. Jielong's innovative drug Imelstat in the clinical stage, targeting diseases such as myelodysplastic syndrome and myelofibrosis, may bring greater market potential.

2. With the improvement of the industry environment and policy support, Jielong is expected to achieve further growth in high-end medical needs.

3. The optimistic expectations for Jielong's future development may attract more investors' attention, further boosting its market share.

Risks

1. Although operating revenue has grown significantly, net losses have widened to US$149 million, indicating that the company still faces pressure in profitability.

2. Intensified industry competition and changes in the policy environment may affect the company's future market performance.

3. The uncertainty of innovative drug development and the risk of clinical trials may impact the company's future revenue.